Life sciences

At the forefront of a changing industry

Life Sciences companies continue to respond to a changing global landscape, and strive to pursue innovative solutions to address today's most pressing challenges. The Life Sciences and Health Care industry group understands the complexity of these challenges, and works with clients worldwide to drive progress and bring discoveries to life. As technology, government, and research shape the evolution of the life sciences industry, Deloitte's global network can help clients address today's challenges and prepare for the future. To learn more about Deloitte's global industry practice and the services offered to clients, contact the LSHC group.

2013 Global life sciences sector outlook 2014 Global life sciences sector outlook
Resilience and reinvention in a changing marketplace.
Health care reform and life sciences: Threat, opportunity or both? New businesses, new markets
The Financial Times and Deloitte bring you the 2013 Global Pharma/Biotech Conference, 3-4 December, London. Join the discussion with executives on the industry’s most pressing issues.
2013 Global life sciences sector outlook Transforming commercial models to address new health care realities
Imperative for biopharmaceutical companies to explore alternative commercial models to supplement traditional go-to-market strategies.
Impact of European Austerity on Pharmaceutical policy and pricing Impact of European austerity on pharmaceutical policy and pricing
A UK Deloitte Centre for Health solutions report that looks to understand the current European pharmaceutical market, the mechanisms for reducing pharmaceutical spending, the future of the pharmaceutical landscape, and the actions the pharmaceutical industry needs to take to survive current austerity.
Transformation beyond reform: A changing life sciences & health care industry Transformation beyond reform: A changing life sciences & health care industry
In conjunction with the Financial Times/Deloitte 2013 Health Care & Life Sciences conference, explore what lies ahead for global life sciences companies as they focus on the practicalities of dealing with the provisions and impacts of U.S. health care reform.